OncoGenex Technologies, based in Vancouver, is a clinical-stage biotechnology company developing targeted therapeutics that address treatment resistance in cancer patients. OncoGenex was spun-out from the Prostate Centre at Vancouver General Hospital, western Canada’s largest hospital and the principal teaching hospital of the University of British Columbia.

Their lead compound, custirsen, is currently in Phase 3 development as a treatment for men with metastatic castrate-resistant prostate cancer and patients with advanced, unresectable non-small cell lung cancer. It is the only compound in development designed to inhibit the production of clusterin, a protein commonly over-produced in cancer cells, and one cause of treatment resistance. OncoGenex has entered into a global collaboration and license agreement with Teva to develop and commercialize custirsen.

In addition, the company is developing OGX-427, a second generation antisense drug that inhibits the production of Hsp27. Elevated levels of Hsp27 are often found in human cancers and expression can be further enhanced as a result of certain cancer treatments. Preliminary data from a Phase 2 trial in chemotherapy-naïve patients with metastatic castrate-resistant prostate cancer showed a higher number of patients without disease progression at 12 weeks and greater declines in PSA and circulating tumor cells with OGX-427 plus prednisone compared to prednisone alone. OGX-427 is also in a Phase 2 clinical trial in patients with metastatic bladder cancer.

For more information visit: http://www.oncogenex.com/